Endo International (NASDAQ:ENDP) (TSE:ENL) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Tuesday, ValuEngine reports.
Other equities analysts also recently issued reports about the stock. Goldman Sachs Group assumed coverage on shares of Endo International in a report on Monday, July 27th. They issued a “sell” rating and a $3.00 price objective on the stock. BidaskClub cut shares of Endo International from a “sell” rating to a “strong sell” rating in a report on Friday, August 14th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Endo International in a research note on Thursday, June 11th. Finally, SunTrust Banks reaffirmed a “buy” rating on shares of Endo International in a research note on Wednesday, July 8th. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $5.33.
Shares of ENDP opened at $2.87 on Tuesday. Endo International has a twelve month low of $1.97 and a twelve month high of $7.10. The firm’s 50 day moving average price is $3.25 and its two-hundred day moving average price is $3.88. The firm has a market cap of $691.75 million, a P/E ratio of -4.10 and a beta of 1.42.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.30. The firm had revenue of $687.59 million for the quarter, compared to analyst estimates of $637.99 million. Endo International had a negative net margin of 5.25% and a negative return on equity of 91.41%. As a group, research analysts forecast that Endo International will post 2.12 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in ENDP. Russell Investments Group Ltd. increased its position in Endo International by 58.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 360,145 shares of the company’s stock valued at $1,233,000 after purchasing an additional 132,234 shares during the period. Geode Capital Management LLC increased its position in Endo International by 4.0% during the 1st quarter. Geode Capital Management LLC now owns 3,315,646 shares of the company’s stock valued at $12,267,000 after purchasing an additional 126,177 shares during the period. Acadian Asset Management LLC acquired a new stake in Endo International during the 1st quarter valued at approximately $402,000. Teza Capital Management LLC increased its position in Endo International by 594.2% during the 2nd quarter. Teza Capital Management LLC now owns 115,013 shares of the company’s stock valued at $394,000 after purchasing an additional 98,445 shares during the period. Finally, AJO LP acquired a new stake in shares of Endo International during the 2nd quarter worth approximately $200,000. 80.21% of the stock is owned by institutional investors and hedge funds.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Article: What is a Backdoor Roth IRA?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.